NASDAQ:QTTB Q32 Bio Inc. Stock

What changed lately

• Latest news release · Sep 30, 2026

  Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

• Latest deck · Sep 30, 2026

  EADV Congress 2026

  Conference · 16 slides

Latest news

All Q32 Bio Inc. news

Financings

• Public offering of common stock and pre-funded warrants

  Aug 5, 2026

  Closed: US$200M raised · US$18.25 a share · Morgan Stanley +4

  Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Cantor (co-lead), Oppenheimer & Co., H.C. Wainwright & Co.

  Use of proceeds: With existing cash, fund operations through topline Phase 3 results of the planned registration-directed bempikibart program in severe or very severe AA

  Announced Jul 13, 2026 · Update Jul 15, 2026 · Closed Aug 5, 2026

Read by 6ix AI from the company's releases

Decks

• EADV Congress 2026

  Conference · 16 slides · Sep 30, 2026

• Technical Presentation (July 2026)

  Technical · 24 slides · Jul 13, 2026

• American Academy of Dermatology Late Breaker Session 2025

  Conference · 16 slides · Mar 8, 2025

• Investor Presentation (January 2025)

  Investor deck · 34 slides · Jan 13, 2025

Q32 Bio Inc. on 6ix

Sector

Health care

Industry

Biotechnology

News releases

19 in the last 12 months · 110 in all · newest Sep 30, 2026 · oldest 2020

Decks

7 decks · latest Sep 30, 2026

Where Q32 Bio Inc. is listed

Log in to ask 6ix AI your own questions about Q32 Bio Inc.